人乳头瘤病毒疫苗接种与自身免疫性疾病风险:法国逾200万年轻女孩的大型队列研究
本研究利用法国全国数据库,纳入2008至2012年间13至16岁、无HPV疫苗接种史和自身免疫性疾病史的参保女孩,比较暴露与未暴露者14类自身免疫性疾病的发病率。在2,252,716名女孩中,37%接种了HPV疫苗,平均随访33个月发生4,096例自身免疫性疾病;除吉兰-巴雷综合征(GBS)外,自身免疫性疾病风险未升高,GBS调整后HR为3.78(1.79-7.98),作者认为需进一步研究确认。
要点
- 在2252716名13-16岁女孩中,37%接种HPV疫苗,平均随访33个月发生4096例自身免疫性疾病。
- 除吉兰-巴雷综合征外,HPV疫苗接种后自身免疫性疾病发病率未升高。
核心结论
- 研究就HPV疫苗接种后自身免疫性疾病风险提供了令人安心的结果,但检测到吉兰-巴雷综合征风险似乎升高,需进一步研究确认该发现。
研究设计与样本
- 基于法国全国数据库的队列研究,纳入2008至2012年间13-16岁、参保一般健康保险计划且无HPV疫苗接种史和自身免疫性疾病史的女孩,随访至发生自身免疫性疾病。
- 研究共纳入2,252,716名女孩,平均随访33个月,采用调整纳入年份、地理区域、社会经济指标、医疗服务使用水平和其他免疫接种的Cox模型比较暴露与未暴露者的自身免疫性疾病发病率。
主要发现
- 在2,252,716名女孩中,37%接种了HPV疫苗,平均随访33个月期间共发生4,096例自身免疫性疾病。
- 除吉兰-巴雷综合征外,暴露于HPV疫苗接种后自身免疫性疾病发病率未升高。
- 该关联在多项敏感性分析中持续存在,且在接种疫苗后最初数月尤为明显。
- 在因果关系假设下,每10万名接种疫苗的女孩中可归因于HPV疫苗的吉兰-巴雷综合征病例为1-2例。
关键数值与推荐
- 通过ICD-10编码(分配于住院和长期疾病)或标志性药物识别14类神经系统、风湿病学、血液学、胃肠道或内分泌自身免疫性疾病。
局限性
- 原文结论指出需进一步研究以确认吉兰-巴雷综合征风险升高的发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whether human papillomavirus (HPV) vaccination could induce or trigger autoimmune diseases (AID) has been questioned, and potentially contributes to low immunization coverage in France. This study evaluated the association between HPV vaccination and the risk of AID using routinely collected data sources. METHODS: All girls aged 13-16years between 2008 and 2012, covered by the general health insurance scheme and without history of HPV vaccination or AID, were included and followed using French nationwide databases. Fourteen neurological, rheumatological, haematological, gastrointestinal or endocrine AID, were identified from ICD-10 codes allocated to hospital stays and long-term illnesses or by marker drugs. Their incidence was compared between girls exposed and non-exposed to HPV vaccination, using a Cox model adjusted for inclusion year, geographic area, socio-economic indicators, healthcare use level and other immunizations. RESULTS: Among 2,252,716 girls, 37% received HPV vaccine and 4,096 AID occurred during a mean follow-up time of 33months. The incidence of AID was not increased after exposure to HPV vaccination, except for Guillain-Barré syndrome (GBS) (incidence rate of 1.4 among exposed [20 cases] versus 0.4 per 100,000 PY among unexposed [23 cases]; adjusted HR: 3.78 [1.79-7.98]). This association persisted across numerous sensitivity analyses and was particularly marked in the first months following vaccination. Under the hypothesis of a causal relationship, this would result in 1-2 GBS cases attributable to HPV vaccine per 100,000 girls vaccinated. CONCLUSIONS: Our study provides reassuring results regarding the risk of AID after HPV vaccination, but an apparently increased risk of GBS was detected. Further studies are warranted to confirm this finding.
引用
- Miranda S, Chaignot C, Collin C, et al. Human papillomavirus vaccination and risk of autoimmune diseases: A large cohort study of over 2million young girls in France. Vaccine. 2017. PMID: 28750853. doi:10.1016/j.vaccine.2017.06.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。